Please login to the form below

Not currently logged in
Email:
Password:

Baxter to acquire ApaTech equity

Baxter will acquire all of ApaTech's outstanding equity for total consideration of up to $330m, in an agreement announced this week

Baxter will acquire all of ApaTech's outstanding equity for total consideration of up to $330m, in a definitive agreement announced this week. 

As part of the aquisition, Baxter will acquire Actifuse, a silicate substituted calcium phosphate synthetic bone graft material that is currently marketed in the US, EU and other select markets around the world. It will also acquire manufacturing and R&D facilities located in the UK, US and Germany.

Ron Lloyd, vice president and general manager, BioTherapeutics and Regenerative Medicine, Baxter, said: "This is a significant step in enhancing Baxter's position in the rapidly growing orthobiologics space, and our leadership in regenerative medicine. Actifuse will allow us to immediately enter the emerging bone fusion category."

ApaTech a private equity-backed, UK-based orthobiologic products company generated sales of approximately $60m in 2009. Baxter and ApaTech will work to ensure uninterrupted operations, product distribution and ongoing support and service for customers, distributors and business partners.

Simon Cartmell, CEO, ApaTech commented: "This is a great event for ApaTech, Baxter, our customers and our employees. The combination of our market presence and insights with the resources of Baxter will enable us to deliver innovative new technologies to more patients worldwide."

The agreement includes an upfront cash payment by Baxter of $240m. Baxter may make additional payments of up to $90m related to the achievement of sales milestones. The transaction is expected to close in the first quarter 2010, subject to customary closing conditions and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

2nd March 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...